I. AMENDMENTS

Amendments to the Claims:

This listing of the claims replaces all prior listings:

1. Canceled.

2. (Previously Presented) A monoclonal antibody which specifically recognizes Aβ11-x peptides wherein said monoclonal antibody, specifically recognizes the first 5 to 7 human amino acids of the β-secretase_11 cleavage site, i.e. Seq Id No.:1 and Seq Id No.:2 or the first 5 to 7 mouse amino acids of the β-secretase_11 cleavage site, i.e. Seq Id No.:3 and Seq Id No.:4, without cross-reacting with full length Aβ1-40/42 peptide, as immunogens.

3. (Previously Presented) The monoclonal antibody as claimed in claim 2 that is detectably labeled.

4. (Previously Presented) The monoclonal antibody as claimed in claim 3 wherein the detectable label is a radiolabel, an enzyme label, a luminescent label or a fluorescent label.

5. (Previously Presented) The monoclonal antibody as claimed in claim 2 that is immobilized on a carrier.

6. (Previously Presented) The monoclonal antibody according to claim 2, expressed by the hybridoma cells J&JPRD/hAβ11/1 and J&JPRD/hAβ11/2 deposited at the Belgian coordinated collection of microorganisms on August 19, 2002 with accession numbers LMBP 5896CB and LMBP 5897CB respectively.

7. (Previously Presented) The hybridoma cells J&JPRD/hAβ11/1 and J&JPRD/hAβ11/2 deposited at the Belgian coordinated collection of microorganisms on August 19, 2002 with accession numbers LMBP 5896CB and LMBP 5897CB respectively.

8. (Previously Presented) An immunoassay method for the determination or detection of Aβ11-x peptides in a sample, the method comprising contacting the sample with an antibody to Aβ11-x peptides as claimed in claim 2 and determining whether an immune complex is formed between the antibody and the Aβ11-x peptide.

9. (Previously Presented) A method for the detection of the presence of Aβ11-x peptides in a tissue sample, the method comprising:

obtaining a tissue sample from the body of a subject;

contacting the tissue sample with an imaging effective amount of the detectably labeled antibody as claimed in claim 3; and

detecting the label to establish the presence of Aβ11-x peptides in the tissue sample.

10. (Previously Presented) A method for the detection of the presence of Aβ11-x peptides in a tissue sample, the method comprising:

obtaining a tissue sample from the body of a subject;

contacting the tissue sample with an imaging effective amount of a detectably labeled, monoclonal antibody which specifically recognizes Aβ11-x peptides; and

detecting the label to establish the presence of Aβ11-x peptides in the tissue sample;

wherein the antibody that is detectably labeled, is expressed by at least one of the hybridoma cells as claimed in claim 7.

11. (Previously Presented) A method for the detection of the presence of Aβ11-x peptides in a body fluid sample, the method comprising:

obtaining a body fluid sample from the body of a subject;

contacting the body fluid sample with an imaging effective amount of the detectably labeled antibody as claimed in claim 3; and

detecting the label to establish the presence of Aβ11-x peptides in the body fluid sample.

12. Canceled.

13. Canceled.

14. (Currently Amended) A method for the diagnosis of diseases associated with production of β-amyloid peptides wherein said disease is selected from the group consisting of clinical or pre-clinical Alzheimer's disease~~,~~ and Down's syndrome, ~~Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch-Type or cerebral amyloid angiopathy,~~ comprising

obtaining a sample from a subject in need of said diagnosis;

contacting the sample with an effective amount of the detectably labeled antibody as claimed in claim 3; ~~and~~

detecting the label to determine the presence of Aβ11-x peptides in the ~~tissue~~ sample~~.~~; and

comparing an amount of Ab11-x peptides in the sample to an amount of Ab11-x peptides in a control, wherein ~~the presence~~ an increased amount of Ab11-x

peptides in the sample compared to the amount of Ab11-x peptides in the control ~~of Aβ11-x peptides in the sample~~ indicates the presence of said diesease.

15. (Previously Presented) A diagnostic composition comprising the antibody as claimed in claim 2 and a pharmaceutically acceptable carrier.

16. (Currently Amended) An immunoassay kit for the diagnosis of diseases associated with production of β-amyloid peptides, comprising the antibody as claimed in claim 2 and a solid support for the antibody wherein said disease is clinical or pre-clinical Alzheimer's disease~~,~~ and Down's syndrome~~, Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch-Type or cerebral amyloid angiopathy~~.